Alina Markova, MD, on Topical Ruxolitinib Mechanism of Action in Cutaneous Chronic GVHD

Video

Alina Markova, MD, speaks to the mechanism of action of topical ruxolitinib INCB018424 phosphate 1.5% cream vs oral ruxolitinib and other topical therapies used in the treatment of non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

Alina Markova, MD, a dermatologist and director of inpatient consultative dermatology at Memorial Sloan Kettering Cancer Center, spoke with CancerNetwork® during the 2022 Tandem Meeting, about the mechanism of action for topical ruxolitinib INCB018424 phosphate 1.5% cream (Opselura) in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease (GVHD).

The mechanisms of topical ruxolitinib are similar to oral ruxolitinib (Jakafi), with both targeting the JAK/STAT pathway. Markova also emphasized that topical treatment is unique from others in the space due to a more targeted approach with less toxicity.

Transcript:

As many of us know, oral ruxolitinib is a JAK1/2 inhibitor that was approved for the treatment of both acute and chronic GVHD. Topical ruxolitinib has the same mechanism, it can reduce inflammation in the skin. The JAK/STAT pathway, as we know, plays a role in advancing GVHD, a it’s the same mechanism. As far as how it compares, it’s much more targeted and has less toxicity topically than the other available options that we have.

Reference

Markova A, Prockop SE, Dusza S, et al. Interim results of a pilot, prospective, randomized, double-blinded, vehicle-controlled trial on safety and efficacy of a topical inhibitor of Janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease. Presented at: 2022 Transplantation & Cellular Therapy Meetings; Salt Lake City, UT; April 23-26, 2022. Abstract 390.

Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content